+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Haploidentical transplantation

Haploidentical transplantation

Cancer Treatment and Research 101: 53-77

When allogeneic transplant is indicated and a MSD is not available, most centers first seek an unrelated donor. However, one must avoid undue delays when a donor is not available and family members should be typed to identify the preferred donor amongst the family. Since a family donor can provide access to transplant for almost every patient, a greater effort should be encouraged to improve and expand haploidentical transplantation. The advantages, outlined in Table 1, suggest compelling reason to perfect the use of haploidentical related donors.

(PDF emailed within 1 workday: $29.90)

Accession: 046211952

Download citation: RISBibTeXText

PMID: 10800644

Related references

Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study. Science China. Life Sciences 59(11): 1139-1148, 2016

Co-transplantation of HLA-haploidentical, bone mat-row derived mesenchymal stem cells prevents graft failure and improves hematological recovery in T-cell depleted haploidentical stem cell transplantation. 2007

HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biology of Blood and Marrow Transplantation 20(3): 314-318, 2014

Successful second transplantation from haploidentical donor for graft failure following unrelated cord blood cell transplantation or mismatched related transplantation: 2 cases report. Chinese Medical Journal 119(17): 1489-1493, 2006

T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. Journal of Clinical Oncology 31(10): 1310-1316, 2013

Transplantation of CD6-depleted peripheral blood stem cells after DLA-haploidentical bone marrow transplantation contributes to engraftment and tolerance in a preclinical model of stem cell transplantation. Veterinary Immunology and Immunopathology 144(1-2): 27-35, 2012

Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Seminars in Oncology 39(6): 683-693, 2013

Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematology. American Society of Hematology. Education Program 2013: 370-376, 2014

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2016

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatric Reports 3 Suppl 2: E15-E15, 2011

Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. Biology of Blood and Marrow Transplantation 21(10): 1714-1720, 2016

An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide. American Journal of Hematology 90(6): 541-548, 2015

Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation. Advances in Hematology 2015: 431923-431923, 2015

Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. Journal of Clinical Immunology 32(2): 268-280, 2012